Non-small cell lung cancer (NSCLC) is the second most prevalent type of cancer.
Abstract
Non-small cell lung cancer (NSCLC) is the second most prevalent type of cancer.
With the current treatment regimens, the mortality rate remains high. Therefore + regulatory T cell infiltrates, suggesting that the composition of T cell infiltrates may predict the level of tumor reactivity. In conclusion, the effective generation of tumor-reactive and polyfunctional TIL products implies that TIL therapy will be a successful treatment regimen for NSCLC patients.
INTRODUCTION
Non-small cell lung cancer (NSCLC) is one of the most prevalent types of cancer worldwide. With the current treatment regimens, the 5-year survival rate of patients suffering from NSCLC is still limited. Because of the striking effects of immunotherapy in melanoma (1) (2) (3) (4) , recent efforts are directed towards treatment with immunotherapy for NSCLC patients. NSCLC are considered immunogenic, because they often contain high numbers of somatic mutations (often induced by smoking tobacco) (5) , and are well infiltrated by T cells (6) (7) (8) . The functionality of these tumor infiltrated T lymphocytes (TILs) has, however, not been well documented. Treatment with anti-PD-1 is currently standard of care for stage IV NSCLC patients with distant metastasis. This therapy resulted in tumor regression in 17-30% of the patients (9) (10) (11) (12) (13) . The majority of patients with NSCLC thus does not benefit from immune checkpoint blockade. Tumors in these patients utilize different immunosuppressive pathways (14) that need to be overcome in order for immunotherapy to work.
Therefore, additional immunotherapy interventions should be explored for the treatment of NSCLC patients, possibly in combination with the existing anti-PD-1 therapy.
One therapeutic opportunity for intervention is the infusion of TILs. Adoptive transfer of ex vivo expanded TILs has proven highly effective for stage IV melanoma patients (15) , with impressive 50% overall response rates in pretreated patients (1, 2) . Of these melanoma patients, 10-20% experience durable complete remission (1, 2).
Tumor-reactive T cells were already detected in the mid 1990s in NSCLC lesions (16) (17) (18) , and a clinical effect of TIL therapy for stage IV NSCLC patients has been reported, albeit with very minor improvements in survival (19) . The protocols to culture and expand TILs from tumor lesions, and the read-outs to define tumorreactive T cells substantially improved since that time. Therefore, the efficacy to grow tumor-reactive TIL products from NSCLC lesions should be re-assessed, both in terms of cell expansion and the presence of cytokine-producing TILs in response to tumors. Furthermore, it is yet to be determined whether a specific T cell profile in tumor lesions correlates with the level of tumor reactivity of expanded TIL products.
Here, we show that most TIL products contain tumor-reactive T cells. In particular TIL products with high tumor reactivity are polyfunctional. Furthermore, tumor reactivity of the expanded TIL product correlated with the composition of the T cell compartment in the tumor lesions. We conclude that the generation of NSCLCspecific TIL products for therapeutic purposes is feasible and should be reconsidered for clinical application.
Materials and methods

Patient cohort and study design
Between June 2015 and June 2017, 25 treatment-naive NSCLC patients were included in this study. Samples from 2 patients were excluded because of logistic issues. Table 1 Tumor stage and differentiation, and weight of the obtained tissues for this study are shown in Table 2 . Tumor size ranged from T1a-T4 according to the TNM7 system, and specified as adenocarcinoma (n=14), squamous carcinoma (n=5) and as NSCLC not otherwise specified (NOS, n=4). On average 1420 mg tumor tissue was obtained, ranging from 23-9590 mg (Table 2) . 
T cell expansion
TIL cultures were performed as previously described for melanoma-derived TILs (1, containing 5% human serum (HS) (Sanquin), 5% FBS, 50μg/ml gentamycin, 1,25 μg/ml fungizone, and 6000 IU human recombinant (hr) IL-2 (Proleukin, Novartis) (pre-Rapid Expansion Phase; pre-REP). Medium was refreshed on days 7, 9 and 11.
Wells were split when a monolayer of cells was observed in the entire well. When more than 30% of the cells stopped dividing (determined as rounding up of cells), cells were harvested, counted and prepared for an additional culture period of 10-13 days (REP). 1-3 times 2x10 5 live cells/well (1-3 wells/donor) were co-cultured with 5-10x10 6 irradiated PBMCs pooled from 10 healthy donors in 24 wells, 30ng/ml anti-CD3 antibody (OKT-3) (Miltenyi Biotec) and 3000IU/ml IL-2. Typically, cells were passaged at day 5, 7, 9 and 11 and harvested, washed and counted on day 10-13, based on visual assessment of the T cell proliferation state as above. Cells were either tested immediately for reactivity, or cryo-preserved in IMDM containing 10% DMSO (Corning) and 30% FBS until further use.
T cell activation
After thawing and live cell counting as described above, pre-REP and REP T cells 
Stasticial analysis
Statistical analyses were performed with Graphpad Prism 7. Pearson's correlation in combination with linear regression.
RESULTS
High yield of lymphoid cells isolated from NSCLC tumor lesions
We first determined the efficacy of isolating TILs from NSCLC lesions that onderwent lobectomy. 23 patients from treatment-naive stage Ib-IVa NSCLC patients suffering from non-squamouse (n=14), squamous (n=5), or from NSCLC not otherwise specified (n=4) were included in this study (Table 1) . To evaluate the TIL isolation and expansion procedure from the tumor, we also isolated normal lung tissue from the same patients that was harvested as far away as possible from the tumor lesion.
From the tumor digests, we obtained on average 33 (Fig. 1B-D) . Of note, sufficient cell numbers for TIL expansion and phenotypic analysis could be isolated even from tumors of <1 cm 3 ( Table 2) .
Effective TIL expansion from NSCLC tumors
The expansion efficiency of TILs highly depends on the tumor type and the culture protocol (1, 2). We here determined the efficiency of TIL expansion from 17 tumor digests with the rapid expansion protocol (REP) established for melanoma TILs (1,
2). For comparison, we included 9 normal lung tissue digests. Tumor and lung tissue digests were cultured for 10-13 days in the presence of IL-2 (pre-REP), followed by a 10-13 day restimulation with the α-CD3 antibody OKT-3 and IL-2 (REP). During pre-REP, CD3 + T cells from tumor and lung digest expanded on average 4-and 6-fold, respectively (Fig. 1E) . REP cultures expanded CD3 + T cells from the tumor 470-fold and from the lung 570-fold, resulting in an overall expansion of on average 2000-fold for tumor TILs, with a minimum of 540-fold, and 3000-fold lung tissue derived T cells (Fig. 1E) . Thus, even though T cells from normal lung tissue may expand slightly better than those from the tumor, the overall efficiency of expanding NSCLCderived T cells was comparable to recently reported expansions of melanoma-derived (Fig. 1G ). In conclusion, both CD4 + and CD8 + T cells from NSCLC were effectively expanded with the REP culture conditions.
The majority of TIL products contain tumor-specific T cells
We next examined the tumor reactivity of expanded TILs. As a read-out, we measured the production of the pro-inflammatory cytokine IFN-γ by expanded TILs upon co-culture with autologous tumor digest. This production was compared to coculture with normal lung tissue digest, or with medium alone. To distinguish the expanded TILs from the high T cell infiltrates within the tissue digests, we pre-stained the expanded TILs with CD4 and CD8 antibodies prior to co-culture.
IFN-γ producing T cells in response to tumor tissue were detected in 16/17 tumor digests ( Fig. 2A,B) . On average, 6.3±7.8% of the T cells from the TIL products produced IFN-γ when co-cultured with tumor digests ( Fig. 2A,B) . We detected similar percentages of IFN-γ-producing T cells within the total CD4 + and CD8 + T cell population, with 5.8±6.3% and 6.5±9.4% of each population, respectively ( Fig.   2A,B) .
Interestingly, we detected 2.3±2.9% IFN-γ-producing T cells in the TIL products upon co-culture with lung digests, which was higher than those of TILs cultured with medium alone (1.1±1.0%; Fig. 2A,B) . The reactivity could be due to undetected tumor cell dissemination, distal tumor antigen presentation by dendritic cells, bystander T cells that are not tumor-specific and thus may also respond to normal lung cells (21) . The reactivity to normal lung tissue digests could also reflect innate immune responses by T cells that are triggered in a non-antigen specific manner (22, 23) . We only considered TIL products tumor-reactive when the percentage of IFN-γ producing T cells was higher in response to the tumor digest than that to the normal lung digest. 13/17 (76%) of the TIL products fulfilled this requirement (see also below). These data therefore indicate that tumor-reactive T cells are highly prevalent in expanded TIL products from NSCLC.
The percentage of T cells producing IFN-γ varied considerably between donors, ranging from 0.3% to 27.5% (Fig. 2B ). This variation in tumor-reactivity could result from high heterogeneity of NSCLC tumors and thus depend on the tumor region that was isolated for TIL expansion. However, we consider this possibility unlikely, because the percentage of IFN-γ + T cells expanded from whole tumor lysates was comparable to that of TILs that were expanded from three distinct parts of the same tumor (Fig. 2C) . Furthermore, all TIL products produced substantial levels of IFN-γ in response to PMA/ionomycin stimulation (65.8±16.4%; Fig. 2D ). There was no significant correlation between this potential to produce cytokines and the tumorreactivity of TIL products (r=0.11, p=0.663). We therefore conclude that the majority of NSCLC-derived TIL products contain tumor-reactive T cells, but that the proportions thereof are variable.
IFN-γ-producing tumor-reactive T cells express CD137 (4-1BB) and CD154 (CD40L)
We next interrogated if measuring the production of IFN-γ alone was sufficient to reflect the actual tumor-reactivity of TIL products. We therefore included the analysis of markers that are rapidly induced upon T cell activation, such as the costimulatory molecules CD137 (4-1BB) (24) , and CD154 (CD40L) (25) . When expanded TILs were co-cultured for 6h with tumor digest, we found a significant induction of CD137 expression in both CD4 + and CD8 + T cells (Fig. 3A, B , top panels). Furthermore, CD4 + T cells -but not CD8 + T cells -showed increased expression of CD154, a marker that was shown to identify antigen-specific CD4 + T cells in the peripheral blood (25) (Fig. 3A, B , middle panels). CD279 (PD-1) expression instead was not induced under these culture conditions (Fig. 3A, B , bottom panels), suggesting that the tumor-reactive T cells are not (immediately) susceptible to negative regulation by immunological checkpoints.
The majority of IFN-γ producing CD8 + T cells were CD137-positive (Fig. 3C,D) .
Combining the expression of CD137 and CD154 with the production of IFN-γ in fact helped to accurately define the presence of tumor-reactive TILs, in particular when the percentage of IFN-γ production was low, and/or the background levels high.
However, we also observed that IFN-γ-negative T cells can express CD137 and CD154 (Fig. 3E,F) , suggesting that the actual percentage of tumor-reactive T cells may be higher than estimated based on the production of IFN-γ.
NSCLC-reactive TILs produce TNF-α and IL-2, and can be polyfunctional
In addition to IFN-γ, other cytokines such as TNF-α and IL-2 play a critical role in effective T cell mediated immunity (26, 27) . This prompted us to determine whether TIL products from NSCLC produced these two cytokines. Interestingly, exposure to tumor digest resulted in significant induction of both TNF-α-and IL-2-producing T cells when compared to co-culture with lung digest or medium alone (Fig. 4A, B ).
This was observed for both CD8 + T cells, and for CD4 + T cells (Fig. 4A, B) .
When we used all three cytokines to define tumor-reactive TILs above background levels (i.e. subtracting the response against lung tissue), again 13/17 TIL products (76.5%) were tumor reactive ( Polyfunctional T cells that produce more than one cytokine simultaneously are considered the most potent effector T cells against chronic infections (28, 29) . This is also observed for T cell responses against tumors (26, 27) . We therefore investigated whether NSCLC-derived TIL products contain these polyfunctional T cells.
Strikingly, all high responders contained T cells that produced 2 or 3 cytokines (Fig.   4B , right panel). Of the 8 intermediate responders, also two patients, #7 and #11, contained polyfunctional T cells (Fig. 4B, right panel) . Polyfunctional responses to tumor digests were observed for both CD4 + and CD8 + T cells (Fig. 4B, right panel) .
Interestingly, in the high responders, tumor-reactive T cells were equally distributed between CD4 + and CD8 + T cells (Fig. 4B, right panel) , and the overall ratio of CD8 + T cells over CD4 + T cells in REP products of high responders was close to 1, whereas this ratio was not skewed to either T cell subset in the intermediate/no responders (Fig. 4C ).
In conclusion, most TIL products contained tumor-reactive CD4 + and CD8 + T cells, and in particular high responders contained polyfunctional T cells, indicative for potent anti-tumoral TIL products generated from NSCLC tumors.
Tumor-specific alterations in T cell composition correlate with tumor-reactivity of TIL products
We next investigated whether the high variation in tumor reactivity between TIL products related to specific features of T cells in the original tumor tissue in situ.
Because the composition of T cell infiltrates is highly variable between individuals
(see below), we used the normal lung tissue as base line for each patient to define the tumor-specific T cell signature.
Tumor tissues showed a modest, but significant increase in CD8 + T cell infiltrates compared to lung tissue, a feature that was not observed for CD4 + T cells (Fig. 5A) .
Interestingly, tumor lesions contained significantly more FOXP3 + CD25 high CD4 + T cells (Fig. 5B) . These FOXP3 + CD4 + T cells did not express the IL-7 receptor alpha chain (CD127), identifying them as bona fide regulatory T cells (30) (Fig. 5B) .
The percentages of CD8 + T cells that express both the integrin CD103 and the retention marker CD69 in the tumor lesion significantly exceeded those in normal lung, which were already high (Fig. 5C We next investigated whether a specific ex vivo tumor-specific T cell signature correlated with the level of tumor-reactivity detected in the TIL products. To account for the high variation between patients already in the healthy lung (Fig 5) , we used the tumor-specific increase of T cell subpopulations for this comparison (delta percentage; ∆ %). The tumor-specific infiltration by CD4 + or CD8 + T cells did not correlate with the percentage of cytokine producing TILs (Fig. 6A) . However, when examining specific T cell subsets, we found that the percentage of CD69 + CD103 + CD8 + T cells positively correlated with the level of tumor-reactivity of expanded TIL products (Fig. 6B ). For CD4 + T cells, a positive correlation with tumor-reactivity was found for the percentage of PD-1 hi CD4+ T cells (Fig. 6B,C) . Intriguingly, even though regulatory T cells are associated with a poor prognosis for NSCLC patients (17, 18) , we found that the presence of tumor-specific FOXP3 + CD25 hi CD4 + T cell infiltrates correlated positively with cytokine production of expanded TILs (Fig. 6D) .
Combined, our data suggest that the tumor-specific signature of CD4 + and CD8 + T cells and a high number of Treg infiltrates is indicative for strong tumor reactivity in the expanded TIL products.
DISCUSSION
Here we show that tumor-specific TILs can be effectively expanded from the majority of NSCLC patients. Importantly, we found that TIL products that contain high percentages of tumor-reactive T cells produce not only IFN-γ, but also TNF-α and/or IL-2. T cells producing more than one cytokine are considered highly potent (26, 27) and vaccination strategies strive to generate these polyfunctional T cell responses (31) . We therefore hypothesize that infusion of TIL products containing polyfunctional T cells should be effective against NSCLC.
Recently, it was shown that tumor-reactive TILs could be expanded from 80% of identify the patients that are most likely to benefit from TIL therapy.
In conclusion, we here demonstrate that most tumor-reactive TIL products generated from NSCLC tumor lesions contain tumor-reactive T cells. We therefore suggest that TIL therapy should be considered as treatment for NSCLC patients. 
